HARD-TO-HEAL WOUNDS
Hard-to-heal wounds, including chronic wounds, represent a significant clinical and organizational challenge for healthcare systems.
The complex nature of the healing process, patients’ comorbidities, and the limited effectiveness of existing solutions indicate the need for new, innovative product approaches. For these reasons, hard-to-heal wounds have been selected as the first area of development within the Synerixa platform.
Within this area, the first Class III medical device project is currently being developed. The formulation phase has been completed, and the project has entered the biocompatibility assessment stage as part of its structured regulatory development pathway.
HARD-TO-HEAL WOUNDS
Hard-to-heal wounds, including chronic wounds, represent a significant clinical and organizational challenge for healthcare systems.
The complex nature of the healing process, patients’ comorbidities, and the limited effectiveness of existing solutions indicate the need for new, innovative product approaches. For these reasons, hard-to-heal wounds have been selected as the first area of development within the Synerixa platform.
Within this area, the first Class III medical device project is currently being developed. The formulation phase has been completed, and the project has entered the biocompatibility assessment stage as part of its structured regulatory development pathway.
HARD-TO-HEAL WOUNDS
Hard-to-heal wounds, including chronic wounds, represent a significant clinical and organizational challenge for healthcare systems.
The complex nature of the healing process, patients’ comorbidities, and the limited effectiveness of existing solutions indicate the need for new, innovative product approaches. For these reasons, hard-to-heal wounds have been selected as the first area of development within the Synerixa platform.
Within this area, the first Class III medical device project is currently being developed. The formulation phase has been completed, and the project has entered the biocompatibility assessment stage as part of its structured regulatory development pathway.
PSORIASIS
Psoriasis is a chronic inflammatory skin condition affecting approximately 2–4% of the global population and represents a significant and growing clinical and quality-oflife burden. Its recurrent nature, visible symptoms and associated discomfort create sustained demand for welltolerated, science-based product approaches addressing local inflammatory processes and skin barrier integrity. Against this background, psoriasis has been selected as a key development focus within the Synerixa platform.
A dedicated research program has been completed. The study demonstrated reduction of visible psoriasis-related symptoms, decrease in local inflammatory signs, confirmed safety of the tested formulations, good tolerability profile, and no observed phototoxic effect.
Further development pathways are currently under strategic evaluation.
PSORIASIS
Psoriasis is a chronic inflammatory skin condition affecting approximately 2–4% of the global population and represents a significant and growing clinical and quality-oflife burden. Its recurrent nature, visible symptoms and associated discomfort create sustained demand for welltolerated, science-based product approaches addressing local inflammatory processes and skin barrier integrity. Against this background, psoriasis has been selected as a key development focus within the Synerixa platform.
A dedicated research program has been completed. The study demonstrated reduction of visible psoriasis-related symptoms, decrease in local inflammatory signs, confirmed safety of the tested formulations, good tolerability profile, and no observed phototoxic effect.
Further development pathways are currently under strategic evaluation.
FUTURE AREAS OF APPLICATION
The Synerixa platform has been designed to enable the development of additional products across various market segments.
These areas remain at the conceptual stage and will be developed in line with the platform’s strategic roadmap.
FUTURE AREAS OF APPLICATION
The Synerixa platform has been designed to enable the development of additional products across various market segments.
These areas remain at the conceptual stage and will be developed in line with the platform’s strategic roadmap.
PSORIASIS
Psoriasis is a chronic inflammatory skin condition affecting approximately 2–4% of the global population and represents a significant and growing clinical and quality-oflife burden. Its recurrent nature, visible symptoms and associated discomfort create sustained demand for welltolerated, science-based product approaches addressing local inflammatory processes and skin barrier integrity. Against this background, psoriasis has been selected as a key development focus within the Synerixa platform.
A dedicated research program has been completed. The study demonstrated reduction of visible psoriasis-related symptoms, decrease in local inflammatory signs, confirmed safety of the tested formulations, good tolerability profile, and no observed phototoxic effect.
Further development pathways are currently under strategic evaluation.
FUTURE AREAS OF APPLICATION
The Synerixa platform has been designed to enable the development of additional products across various market segments.
These areas remain at the conceptual stage and will be developed in line with the platform’s strategic roadmap.